News and Resources
News and resources
Japanese investors offered new opportunity to purchase life-saving vaccine bonds
The International Finance Facility for Immunisation Company (IFFIm), in collaboration with the GAVI Alliance, the World Bank and HSBC, will offer a new issue of “vaccine bonds” to Japanese retail investors. [日本語]
World leaders describe IFFIm as a “catalytic success”
Official report says IFFIm has been "game changing" for global immunisation Washington DC, 22 May 2012 - IFFIm is highlighted as “a catalytic success story” by the G8 in the official report from the 2012 meeting at Camp David. The “Camp David Accountability Report” focuses on areas of agreement on global health, food security and n...
René Karsenti to become new Chair of IFFIm Board
Outgoing Chair Alan Gillespie oversaw raising of US$ 3.6 billion René Karsenti will take over as IFFIm Board Chair on 24 February Washington DC and Geneva, 3 February 2012 - René Karsenti has been appointed as the new Board Chair of the International Finance Facility for Immunisation (IFFIm). He joined the Board on 23 December 2011 and will take ...
IFFIm rating action by Standard & Poor’s follows sovereign donor downgrades
Standard & Poor’s downgrades the International Finance Facility for Immunisation Company by one notch from AAA to AA+ Washington DC, 17 January 2012 - Standard & Poor’s (S&P) has downgraded the International Finance Facility for Immunisation Company (IFFIm) by one notch from AAA to AA+ with a negative outlook, following S&P’s ratin...
IFFIm and World Bank renew commitment to raise funds for GAVI programmes
IFFIm announces the renewal for five years of its Treasury Management Agreement with the World Bank Washington, 10 October 2011 - The International Finance Facility for Immunisation (IFFIm) is pleased to announce the renewal for five years of its Treasury Management Agreement with the World Bank. "This has been an effective partnership...
New IFFIm vaccine bonds issued to support life-saving immunisation in poorest countries
J.P. Morgan, the World Bank and the International Finance Facility for Immunisation ("IFFIm") today announced the issuance of US$ 169.4 million (equivalent) of IFFIm "Vaccine Bonds" in Japan. [日本語]
Independent evaluation confirms IFFIm success
HLSP analysis finds IFFIm transformative and a 'strong case for further investment' IFFIm saves many additional lives and money, and has helped "transform GAVI from a niche actor into a major player in international health." That's the conclusion of a well-respected, independent health care consulting firm in a new, independent evaluation of...
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.